There are currently 445 ongoing clinical trials involving Renal Cell Carcinoma
Of the 445 trials,148 trials are in Phase II
Furthermore, 254 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Renal Cell Carcinoma, an oncology indication. The largest number of ongoing clinical trials for Renal Cell Carcinoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Renal Cell Carcinoma-related drug trials.
National Cancer Institute US: The leading ongoing Renal Cell Carcinoma related clinical trial sponsor
National Cancer Institute US is the top sponsor for Renal Cell Carcinoma-related ongoing clinical trials.
Bristol-Myers Squibb Co, University of Texas MD Anderson Cancer Center, Merck & Co Inc, and Pfizer Inc are among other notable clinical trial sponsors involved in Renal Cell Carcinoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Renal Cell Carcinoma
Pembrolizumab (Keytruda), Nivolumab (Opdivo, Opdyta), and Bevacizumab (Avastin) are among the key marketed drugs involving Renal Cell Carcinoma.
Pembrolizumab (Keytruda) is an antineoplastic immunomodulating agent. It functions via Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist mechanism of action. eytruda is formulated as lyophilised powder for solution, solution concentrate for intravenous route of administration. Keytruda is marketed for the treatment of Renal Cell Carcinoma and several other indications including Esophageal Squamous Cell Carcinoma (ESCC), Bile Duct Cancer (Cholangiocarcinoma), Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Esophageal Cancer, Adenocarcinoma of The Gastroesophageal Junction, Cervical Cancer, Melanoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Head and Neck Cancer, and Gastric Cancer. Pembrolizumab was first approved in 2014 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by Merck & Co Inc and its subsidiaries.
Bevacizumab (Avastin) is a recombinant humanized monoclonal IgG1 antibody. It functions via Vascular Endothelial Growth Factor A (Vascular Permeability Factor or VEGFA) Inhibitor mechanism of action. It is formulated as injection for intravenous administration. Avastin is marketed for the treatment of Renal Cell Carcinoma and several other indications including Breast Cancer, Lung Cancer, Ovarian Cancer, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Colorectal Cancer, Cervical Cancer. Avastin was first approved in 2004 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by F. Hoffmann-La Roche Ltd and its subsidiaries.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward